A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) (AB02)

Active:	Yes
Cancer Type:	Liver Cancer / Hepatoblastoma	NCT ID:	NCT07221253
Trial Phases:	Phase III	Protocol IDs:	D702NC00001 (primary)
Eligibility:	18 Years and older (Adult, Older Adult ), Male and Female	Study Type:	Treatment
Study Sponsor:	AstraZeneca
NCI Full Details:	https://clinicaltrials.gov/study/NCT07221253

Summary

The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.

Treatment Sites in Georgia

Northwest Georgia Oncology Centers (NGOC) - Cobb Hospital (Marietta)
340 Kennestone Hospital Blvd.
Suite 100
Marietta, GA 30060
770-281-5101

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.